Financial Daily from THE HINDU group of publications
Friday, Sep 02, 2005

Port Info

Group Sites

Corporate - Announcements
Industry & Economy - Health

Wyeth set to bring blockbuster paediatric vaccine to India

P.T. Jyothi Datta

Mumbai , Sept. 1

WYETH is poised to bring its blockbuster — a billion-dollar pediatric vaccine for pneumococcal diseases into India. The vaccine is touted to be the first and only vaccine indicated for children up to two years of age.

The estimated Rs 300-crore company is in the process of getting regulatory clearance from the Drug Controller General of India (DCGI) and expects to launch in India "very shortly", said the Wyeth Ltd's Medical Director, Dr Shilpa Patil.

Pneumococcal diseases are illnesses caused by the bacteria Streptococcus pneumoniae or "Pneumococcus".

And when this bacteria affects the brain it causes meningitis; when it invades the lungs it causes bacterial pneumonia; when it affects the bloodstream, it causes bacteremia.

The vaccine assumes significance given that more than one million children below the age of five years are estimated to die every year of pneumococcal infections in developing countries alone.

Dr Patil told Business Line that the vaccine would be imported from global sites in the US or Europe.

The company will also undertake post-marketing surveillance, the official said.

No details were available on how the vaccine would be priced, but it would be administered in a three-plus-one (booster-shot) schedule, Dr Patil said.

Wyeth is already in the process of putting its logistics together to distribute the product.

While the product will be sold through pediatricians, it is not part of the Government programmes in India.

It is, however, part of the immunisation schedule in the US, Australia and Canada, the official said.

The vaccine is advised for infants below two years and sometimes for children below five years, as they are at the greatest risk for invasive pneumococcal disease.

About 25 to 60 per cent of them are carriers of pneumococci in their throats.

The risks of meningitis and bacteremia are greatest during the first two years of life, the company said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bajaj-US agency combine develops hydrogen-run auto

Reliance gets Rs 10,500-cr excise notice
Eveready to invest Rs 5.5 cr in Oracle e-Biz suite
Volkswagen to return money siphoned off by Vashista Wahan
Nagarjuna Power plant at Udupi to supply 100 MW to Kerala
Wyeth set to bring blockbuster paediatric vaccine to India
Nagarjuna Const bags Rs 108-cr orders
Skoda to roll out Combi this month
Lodha counsel slams Birlas' conduct
MP Birla group forces poll on all resolutions at Pilani Inv AGM
Rahul Bajaj makes in-principle agreement with Shishir
New norms to check misuse of ADR/GDR funds: Ministry
Dr Reddys' grants 8,300 ESOPs
Meet on Dr J.J. Irani report
Escorts in recast mode — Nikhil Nanda appointed COO
Govt to tighten disclosure norms for company deposits
IOC, Caliak to submit bid for 51% stake in Turkish firm
Beeyu Overseas bids for Lankan tea property — Ties up with Colombo-based firm; plans jt venture marketing firm with Tata Coffee
Ranbaxy, Wockhardt ready war chests for acquiring Alpharma
TT to set up new unit in Gujarat
Atlas Copco to expand facilities in Pune, Nashik
Hero Honda Motors to set up third manufacturing plant
Eureka Forbes in pact with BPCL
Madras Cements commissions captive power plant in TN
MCF gets safety management system certificate
Ultimate Hospitality gets quality tag
TVS Motor to roll out bikes in Indonesia by October 2006
Toyota conducting feasibility study on entering small car segment
IOC calls again for petro products price hike
Bajaj Auto sales up 34 pc in August
Tata Motors sales up 20 pc in August
Maruti sales up 9.5 pc in Aug
TVS Motor 2-wheeler sales up 15 pc
India Inc eyes jatropha farming in a big way

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line